CDKN2A and neoplasm: The classical subtype is defined by epidermal growth factor receptor (EGFR) amplification, loss of PTEN, and mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A), all of which contribute to aggressive tumor behavior and a negative prognosis.